What We Do Matters
Richard Cornell is working to change the face of bone healing treatments with the risk of bacterial infection. Currently, many "next generation" antibiotics are so closely related to existing antibiotics that bacteria quickly evolve resistance to them. Simply modifying existing antibiotics like this simply does not work.
Mission and Impact
Our mission is to develop innovative solutions that revolutionise anti-infective musculoskeletal treatments that promote bone healing, reducing healthcare costs, and offering patients a faster and safer recovery process.
Our products are effective against key bacteria, even those with multiple-resistance to current antibiotics. They will help patients with risk of these infections leave hospital sooner, it will free up precious and costly healthcare resources like hospital beds and ease the burden on specialist medical and support staff.
Founder and Company History
Richard Cornell was established in 2019 by Professor Edward Draper as a pre-seed startup to develop and take our technologies to market.
Prof Draper is a successful inventor with 66 patents (in nine families), 35 of which are as sole inventor. He is one of the three inventors on our patent filed in 2022. He has raised over 30 major R&D grants (Value £13M), 17 as SME partner (10 as lead).
​
In industry as Innovation Manager, he has directly managed departments of: Regulatory Affairs, New Product Development, and the grant-raising R&D. He has supervised the technical aspects of medical devices development and market launch across the globe.
